Navigation Links
Nanotechnology Could Revolutionize Cardiac Treatment

Scientists have developed nanomolcecules called ‘nanolipoblockers’ that guard against bad cholesterol. The molecules are designed in such a way that they offer a local therapeutic effect,// aimed at reducing the recurrence of blocked blood vessels in cardiac patients. These nanoengineered molecules, which represent the first line of defense against harmful cholesterol could soon join the fight against heart disease, perhaps even help prevent it in high-risk individuals.

In a paper scheduled for publication June 12 in the American Chemical Society's journal Biomacromolecules and now appearing on that journal's Web site, Rutgers researchers propose a way to combat clogged arteries by attacking how bad cholesterol triggers inflammation and causes plaque buildup at specific blood vessel sites. Their approach contrasts with today's statin drug therapy, which aims to reduce the amount of low-density lipids, or LDLs (‘bad’ cholesterol), throughout the body.

In an ironic twist, the Rutgers approach aims to thwart a biological process that is typically beneficial and necessary. Prabhas Mogue, the principal investigator and associate professor of biomedical engineering and chemical and biochemical engineering at Rutgers, said that vascular plaque and inflammation develop when certain forms of LDL are attacked by white blood cells that scavenge cellular debris and disease agents. ‘While these scavengers, called macrophages, perform an essential role in keeping organisms healthy, their interaction with highly oxidized LDL molecules has quite the opposite effect,’ he said.

Mogue explains that macrophages accumulate large amounts of oxidized LDL and secrete chemicals that can damage the neighboring tissues and, ultimately, become fatty foam cells. The researchers' approach, therefore, is to create clusters of nanoengineered molecules that target specific receptor molecules on cell membranes and block these oxidized LDLs from attaching to macrop hages.

Mogue is working with Kathryn Uhrich, Rutgers professor of chemistry and chemical biology, who is an expert at synthesizing biologically useful molecules at the nanoscale – anywhere from 10 to 100 nanometers long. The research team, which also includes graduate student Evangelia Chnari and synthetic chemists Lu Tian and Jinzhong Wang, has designed a family of nanolipoblockers, or NLBs, which compete with oxidized LDL for a macrophage's attention. The NLBs bind to receptor sites on macrophages, cutting the accumulation of oxidized LDL by as much as 75 percent.

The NLB particles are made of several engineered organic strands or chains whose ends cluster around a central point, creating a structure known as a micelle. Uhrich synthesized molecule chains with several different characteristics, such as attracting or repelling water or having a positive or negative charge. When the chains assembled into micelles, Mogue tested them for how well they blocked LDL uptake.

‘We're employing the tools of nanotechnology – specifically tailoring the structure of the molecule, changing groups on the ends of the chains and closely analyzing which forms of the particles bind to the different macrophage receptors,’ Uhrich said. ‘The significant finding of our study is that the nanoscale organization matters tremendously for blockage of oxidized LDL, which opens new avenues for more specific targeting of receptors.’

Mogue said that if this method proves feasible in living organisms, it could convey treatment to the site of the problem, rather than a systemic approach. ‘While statins are a great stride in preventing cardiovascular disease, they are not suitable for everyone,’ Mogue said. ‘Our approach also has potential to topically address the recurrence of inflammation and blockage at stent surgery sites, something that systemically active drugs have not been shown to consistently do.’

Research to test the performance of NLBs in living organisms is now under way.

Soure: Eurekalert
'"/>




Related medicine news :

1. CoQ10 bioavailability increased by Nanotechnology
2. Nanotechnology Revolution To Be Spearheaded By European Union
3. RNA Nanotechnology To Rescue Cancer Patients In Future
4. Scientists Consider About New Technology Called Nanotechnology
5. Potential Benefits Of New Nanotechnology
6. Nanotechnology Promises Huge Medical Benefits
7. Nanotechnology at its best: Nanomotors And Mechanical Nanoswitches
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Nanotechnology – to detect and treat ovarian cance
10. Nanotechnology Used For Detecting Viruses
11. India, China Trying to Fight Disease With Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology: